Watchlist

Watchlist
AbbVie Inc. (ABBV)
IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield
36 becomes 40 This IRA portfolio was created in 2016 and written about here January 2017. The 36 holdings were 34 stocks and 2 Vanguard Funds and a proposed dividend yield of 4.8%. This update is for mid February- the portfolio was actually up 17% with dividends at the end of Janua…
My Top 10 Retirement Stocks
Over the past few weeks, I've started a series about building a retiree portfolio . In fact, I think there should be a big difference between a retiree portfolio and a retirement portfolio. The retirement portfolio is the nest egg you are actively building. You are looking for growth firs…
Biotech Forum Daily Digest For Feb. 22
Hysteria is impossible without an audience. Panicking by yourself is the same as laughing alone in an empty room. You feel really silly . Chuck Palahniuk The biotech sector was having a solid showing throughout most of the trading day Wednesday. However, the sector and th…
Another Phase III Win For Neurocrine Biosciences
Good news continues to stack up for Neurocrine Biosciences ( NBIX ), with the companys partner AbbVie ( ABBV ) announcing on Wednesday that its first of two Phase III studies of elagolix in uterine fibroids met all of its efficacy endpoints. This continues a pretty good run of succ…
AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference
NORTH CHICAGO, Ill. , Feb. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 . Bill Chase , executive vice president and chief financial officer will present at 7:00 a.m. Central time ….
27 Dividend Increases: February 12-16, 2018 (Part 3: Remaining Sectors)
Monitoring dividend increases for stocks on my watch is one way to identify candidates for further analysis. Last week, 27 companies on my watch list declared dividend increases, including four stocks I own. To create my watch list, I screen the CCC list , using the following filters: M…
Undervalued And Attractive: Pick Up Novartis In 2018
Novartis ( NVS ) latest earnings call has been a mixed bag. While the company confirmed that its 2017 performance was more or less in line or even slight above the guidance, the company has predicted modest growth in revenues and earnings in 2018. Though its recently launched produ…
Your Daily Pharma Scoop: Portola Update, Wave Life Sciences To Collaborate With Takeda, AbbVie Reports Data For Egolix
Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will discuss Portola Pharmaceuticals ( PTLA ), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. Portola reported that the European Medicines Agencys ((EM…
Dividend Companies Showering Shareholders With More Cash
As part of my monitoring process, I review the list of dividend increases every week. I usually focus on companies that have managed to boost dividends to shareholders for at least a decade. It looks like this year may be classified as the year of higher dividend growth. This is because of…
AbbVie's elagolix successful in late-stage uterine fibroid study
A Phase 3 clinical trial, ELARIS UF-I, assessing AbbVie's (NYSE: ABBV ) elagolix in women with uterine fibroids met the primary endpoint . A statistically significant proportion of women (68.5%) receiving elagolix, in combination with low-dose hormone (add-back) therapy, achieved clinical r…
AbbVie Inc. (ABBV)